{
  "id": "86c690cb60c29aab",
  "title": "Press Release : Sanofi venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease",
  "description": "20260202T070000Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2026/02/02/tmt-newswire/globenewswire/press-release-sanofis-venglustat-met-all-primary-endpoints-in-a-phase-3-study-of-type-3-gaucher-disease/2269457",
  "published_at": "20260202T070000Z",
  "fetched_at": "2026-02-03T00:29:56.519436+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2026/02/02/tmt-newswire/globenewswire/press-release-sanofis-venglustat-met-all-primary-endpoints-in-a-phase-3-study-of-type-3-gaucher-disease/2269457",
    "url_mobile": "https://www.manilatimes.net/2026/02/02/tmt-newswire/globenewswire/press-release-sanofis-venglustat-met-all-primary-endpoints-in-a-phase-3-study-of-type-3-gaucher-disease/2269457/amp",
    "title": "Press Release : Sanofi venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease",
    "seendate": "20260202T070000Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2026/02/02/920891.jpg",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}